Search
Biontech SE
BNTXAdd to Watchlist
91.220USD
0.0000.00%
Close 06/26, 16:00（ET）Quotes delayed by 15 min
23.07BMarket Cap
LossP/E TTM
View Detailed Chart
TradingKey 图表Intraday
1m
30m
1h
D
W
M
D
Today
0.00%
5 Days
+0.36%
1 Month
-2.38%
6 Months
-3.49%
Year to Date
-4.18%
1 Year
-14.52%
Key Figures
--Open
0.000High
0.00Volume
LossP/E TTM
LossP/E Dynamic
--Dividend TTM
0.35%Turnover Ratio
91.220Prev. Close
0.000Low
0.00Turnover
LossP/E Static
1.06P/B
0.00%Div Yield TTM
-5.93%ROA
124.00052wk High
0.98Volume Ratio
-665.30MNet Profit
252.88MShares
-4.3892EPS TTM
1.33Beta
-6.66%ROE
79.52052wk Low
2.81%Amplitude
40.47%Gross Margin
23.07BMarket Cap
-3.22Reward/Risk
1.93%Risk Rate
TradingKey Stock Score of Biontech SE
Currency: USD Updated: 2026-06-26Key Insights
Biontech SE's fundamentals are relatively very healthy, and its growth potential is high.Its valuation is considered fairly valued, ranking 78 out of 387 in the Biotechnology & Medical Research industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 128.00.In the medium term, the stock price is expected to remain stable.Despite an average stock market performance over the past month, the company shows strong fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
Biontech SE's Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Score Analysis
Current score
Previous score
Media Coverage
Last 24 hours
Coverage Level
Very Low
Very High
Neutral
Biontech SE Highlights
StrengthsRisks
BioNTech SE is a Germany-based clinical-stage biotechnology company. The Company focuses on patient-specific immunotherapies for the treatment of cancer and other serious diseases. The Company is providing technologies including mRNA-based therapies, cell therapies, small molecules and antibodies, which can be utilized for specific purposes or can be even combined with each other in a synergistic manner. It also develops a broad product pipeline using different scientific approaches and technology platforms, including individualized mRNA-based product candidates, chimeric antigen receptor T-cells, checkpoint immunomodulators, targeted cancer antibodies and small molecules. In addition, the Company offers diagnostic products and drug discovery services for other therapeutic areas, including infectious diseases, allergies and autoimmune disorders.
Fairly Valued
The company’s latest PE is -20.78, at a medium 3-year percentile range.
Institutional Selling
The latest institutional holdings are 51.86M shares, decreasing 2.43% quarter-over-quarter.
Held by Catherine Wood
Star Investor Catherine Wood holds 122.26K shares of this stock.
Analyst Rating
Based on
22
analysts
Buy
Current Rating
128.000
Target Price
+40.32%
Upside Space
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
Biontech SE News
More news coming soon, stay tuned...
Financial Indicators
EPS
Relevant data have not been disclosed by the company yet.
Total revenue
Relevant data have not been disclosed by the company yet.
Biontech SE Info
BioNTech SE is a Germany-based clinical-stage biotechnology company. The Company focuses on patient-specific immunotherapies for the treatment of cancer and other serious diseases. The Company is providing technologies including mRNA-based therapies, cell therapies, small molecules and antibodies, which can be utilized for specific purposes or can be even combined with each other in a synergistic manner. It also develops a broad product pipeline using different scientific approaches and technology platforms, including individualized mRNA-based product candidates, chimeric antigen receptor T-cells, checkpoint immunomodulators, targeted cancer antibodies and small molecules. In addition, the Company offers diagnostic products and drug discovery services for other therapeutic areas, including infectious diseases, allergies and autoimmune disorders.
Ticker SymbolBNTX
CompanyBiontech SE
CEOSahin (Ugur)
Websitehttps://www.biontech.com/
Related Instruments
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%Popular Instruments
FAQs
What is the current price of Biontech SE (BNTX)?
The current price of Biontech SE (BNTX) is 91.22.
What is the symbol of Biontech SE?
The ticker symbol of Biontech SE is BNTX.
What is the 52-week high of Biontech SE?
The 52-week high of Biontech SE is 124.00.
What is the 52-week low of Biontech SE?
The 52-week low of Biontech SE is 79.52.
What is the market capitalization of Biontech SE?
The market capitalization of Biontech SE is 23.07B.
Is Biontech SE (BNTX) currently rated as Buy, Hold, or Sell?
According to analysts, Biontech SE (BNTX) has an overall rating of Buy, with a price target of 128.00.
What is the Earnings Per Share (EPS TTM) of Biontech SE (BNTX)?
The Earnings Per Share (EPS TTM) of Biontech SE (BNTX) is -5.52.
